John Barrett

Point-of-Care Ultrasound Cardiac Echocardiography

John Barrett

Abdominal Aortic Aneurysm

John Barrett

Full-polarization millimeter wavelength variability of Sagittarius A * during the 2018 EHT campaign

Ezequiel Albentosa-Ruíz, E. Washington, N. Marchili, Iván Martí-Vidal et autres

Context. Sagittarius A* (Sgr A * ), the supermassive black hole at the center of the Milky Way, provides a unique laboratory to study accretion dynamics and plasma processes near the event horizon. Aims. We investigated the variability and polarization properties of …

es, us, it, de, rs, cu, sk, nl, jp, ca, my, au, tw, se, cl, fr, cn, kr, mx, Afrique du Sud, dk, gt (code pays fourni par la source)

The Regenerative Vanua Journey: Rekindling the Connection and Regeneration of Vanua through Regenerative Agritourism Experiences

Cherise Addinsall, Jerry Spooner, Anna Pollock, Laurana Rakau-Tokatakee et autres

Summary This case study explores the journey of the not-for-profit Regenerative Vanua, which is an organisation operating in the South Pacific and is responsible for research, training and development support for regenerative agritourism and regenerative landscapes. Since its inception, Regenerative Vanua has …

au, nz (code pays fourni par la source)

P330 Navigating the unknown: an international survey of current dietetic practices for overweight and obesity in people with cystic fibrosis

Julia Snowball, Sarah Collins, Chris Smith, V. Lynch et autres

gb (code pays fourni par la source)

Evaluation and Management of Buprenorphine Extended-Release Injection Thrombophlebitis: A Case Report

John Barrett, Rebecca Schapiro, Emily Casey, Judy Chertok

INTRODUCTION: Buprenorphine extended-release subcutaneous injection (BUP-XR) is a medication used to treat opioid use disorder. It is a long-acting formulation of buprenorphine, which is a partial opioid agonist. Buprenorphine extended-release subcutaneous injection is injected into the subcutaneous space forming a depot that …

us (code pays fourni par la source)

Supplementary Figure 1 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

PDF file - 5868K, A. Tumor growth in mice treated with activated NK cells combined with rituximab was serially measured using in vivo bioluminescence assay. Two mice (NK-No.1* and NK-No.2**) were euthanized at different time points on day 14 and day 18, …

Supplementary Figure 2 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

PDF file - 4938K, A. Representative patterns of tumor growth displayed in mice treated with cCD16ζ-T cells in combination with rituximab in the late phase determined using in vivo bioluminescence assay. In mice treated with cCD16ζ-T cells combined with rituximab, tumor growth …

Data from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

Abstract The central tumoricidal activity of anticancer monoclonal antibodies (mAb) is exerted by FcγR IIIa (CD16)–expressing effector cells in vivo via antibody-dependent cell-mediated cytotoxicity (ADCC), as observed for natural killer (NK) cells. In practice, chemotherapy-induced leukopenia and exhaustion of NK cells resulting …

Supplementary Figure 2 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

PDF file - 4938K, A. Representative patterns of tumor growth displayed in mice treated with cCD16ζ-T cells in combination with rituximab in the late phase determined using in vivo bioluminescence assay. In mice treated with cCD16ζ-T cells combined with rituximab, tumor growth …

Supplementary Figure 1 from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

PDF file - 5868K, A. Tumor growth in mice treated with activated NK cells combined with rituximab was serially measured using in vivo bioluminescence assay. Two mice (NK-No.1* and NK-No.2**) were euthanized at different time points on day 14 and day 18, …

Data from Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto, Hiroaki Asai et autres

Abstract The central tumoricidal activity of anticancer monoclonal antibodies (mAb) is exerted by FcγR IIIa (CD16)–expressing effector cells in vivo via antibody-dependent cell-mediated cytotoxicity (ADCC), as observed for natural killer (NK) cells. In practice, chemotherapy-induced leukopenia and exhaustion of NK cells resulting …